Howard L Elford

Howard L Elford

UNVERIFIED PROFILE

Are you Howard L Elford?   Register this Author

Register author
Howard L Elford

Howard L Elford

Publications by authors named "Howard L Elford"

Are you Howard L Elford?   Register this Author

19Publications

262Reads

23Profile Views

Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.

Mol Cancer Ther 2015 Nov 2;14(11):2411-21. Epub 2015 Sep 2.

Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, California.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-14
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-14-0689DOI Listing
November 2015

The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.

PLoS One 2014 17;9(11):e112619. Epub 2014 Nov 17.

Wake Forest University Health Sciences, Department of Internal Medicine, Section on Hematology and Oncology, Winston-Salem, North Carolina, United States of America; Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112619PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234372PMC
July 2015

Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected mice.

Antivir Ther 2011 ;16(8):1277-86

Department of Internal Medicine, University of California, Davis Health System, Sacramento, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP1893DOI Listing
April 2012

Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model.

Comp Med 2009 Dec;59(6):567-72

Division of University Laboratory Animal Resources and the Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, Ohio, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798842PMC
December 2009

Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells.

Cancer Lett 2007 Jan 20;245(1-2):156-62. Epub 2006 Feb 20.

Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, General Hospital of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835060002
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2006.01.001DOI Listing
January 2007

Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.

Cancer Lett 2006 Feb;233(1):178-84

Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait, and Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Austraia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2005.03.013DOI Listing
February 2006

Oxygen carriers: a selected review.

Transfus Apher Sci 2006 Feb 22;34(1):25-32. Epub 2005 Dec 22.

Department of Clinical Sciences, University of Kentucky, Room 209b, Charles T. Wethington Building, 900 South Limestone Street, Lexington, KY 40536-0200, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2005.09.005DOI Listing
February 2006

Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.

J Pharmacol Exp Ther 2005 Jul 6;314(1):70-6. Epub 2005 Apr 6.

Davis Heart and Lung Research Institute and the Department of Pharmacology, The Ohio State University College of Medicine, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.105.083980DOI Listing
July 2005

Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.

Cancer Chemother Pharmacol 2004 Aug 4;54(2):139-45. Epub 2004 May 4.

General Hospital of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, 5H Waehringer Guertel 18-20, 1090, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0795-0DOI Listing
August 2004

Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.

Life Sci 2004 Jan;74(9):1071-80

Clinical Institute for Medical and Chemical Laboratory Diagnostics, School of Medicine, University of Vienna, General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2003.06.043DOI Listing
January 2004

Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.

Biochem Pharmacol 2002 Aug;64(3):481-5

Clinical Institute for Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical School, University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)01186-3DOI Listing
August 2002